<DOC>
	<DOCNO>NCT00238849</DOCNO>
	<brief_summary>The purpose study determine response rate treatment oxaliplatin Navelbine patient previously treat NSCLC . Oxaliplatin Navelbine clinically evaluate yet . However , Navelbine safely administer platinum compound .</brief_summary>
	<brief_title>Phase II Study Oxaliplatin Navelbine Second-Line Treatment Advanced NSCLC .</brief_title>
	<detailed_description>This non-randomized trial patient previously treat Non-small cell lung cancer . Each patient receive 6 cycle chemotherapy consist Oxaliplatin Navelbine . Oxaliplatin give intravenously every 21 day Navelbine administer Intravenously day 1 day 8 every 21 day .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>Locally advanced metastatic nonsmall cell lung cancer recur , progress , fail respond previous systemic chemo . Measurable disease Good performance status ( ECOG 0,1 2 ) Previously treat Oxaliplatin Navelbine Symptomatic CNS metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>